Neose Technologies Newswire

Neose Technologies Newswire

Comprehensive Real-Time News Feed for Neose Technologies.

Results 1 - 20 of 119 in Neose Technologies

  1. Intec Pharma (NTEC) Hits New 1-Year High at $8.20Read the original story w/Photo

    Wednesday | Daily Political

    Intec Pharma reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $8.20 and last traded at $7.84, with a volume of 14842 shares changing hands.

    Comment?

  2. Intec Pharma (NTEC) Upgraded at BidaskClubRead the original story w/Photo

    Tuesday Dec 11 | Daily Political

    NTEC has been the topic of several other research reports. ValuEngine upgraded shares of Intec Pharma from a hold rating to a buy rating in a research report on Saturday, December 1st.

    Comment?

  3. Intec Pharma (NTEC) Given "Buy" Rating at HC WainwrightRead the original story w/Photo

    Monday Dec 10 | AmericanBankingNews.com

    The firm presently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price target indicates a potential upside of 109.97% from the stock's previous close.

    Comment?

  4. Intec Pharma (NTEC) Downgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Sunday Dec 9 | IntersportsWire

    According to Zacks, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology.

    Comment?

  5. Intec Pharma (NTEC) Hits New 12-Month High at $8.08Read the original story w/Photo

    Saturday Dec 8 | IntersportsWire

    Intec Pharma shares reached a new 52-week high on Thursday . The company traded as high as $8.08 and last traded at $8.00, with a volume of 8297 shares traded.

    Comment?

  6. Intec Pharma (NTEC) Sets New 52-Week High at $8.08Read the original story w/Photo

    Friday Dec 7 | Daily Political

    Intec Pharma reached a new 52-week high during trading on Thursday . The stock traded as high as $8.08 and last traded at $8.00, with a volume of 8297 shares.

    Comment?

  7. Oppenheimer Reiterates "$15.00" Price Target for Intec PharmaRead the original story w/Photo

    Thursday Dec 6 | IntersportsWire

    The firm currently has a buy rating on the biotechnology company's stock. Several other equities analysts have also weighed in on NTEC.

    Comment?

  8. Brokerages Expect Intec Pharma (NTEC) to Announce -$0.31 EPSRead the original story w/Photo

    Tuesday Nov 27 | AmericanBankingNews.com

    Brokerages expect Intec Pharma to announce earnings per share of for the current fiscal quarter, according to Zacks Investment Research . Zero analysts have provided estimates for Intec Pharma's earnings.

    Comment?

  9. Analysts Set Intec Pharma (NTEC) Target Price at $11.60Read the original story w/Photo

    Sunday Nov 25 | IntersportsWire

    Intec Pharma has received a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company.

    Comment?

  10. Intec Pharma (NTEC) Receives Average Rating of "Buy" from BrokeragesRead the original story w/Photo

    Tuesday Nov 20 | AmericanBankingNews.com

    Shares of Intec Pharma have been given a consensus recommendation of "Buy" by the seven ratings firms that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation.

    Comment?

  11. Migdal Insurance & Financial Holdings Ltd. Purchases 67,929 Shares of Intec PharmaRead the original story w/Photo

    Sunday Nov 18 | AmericanBankingNews.com

    Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Intec Pharma by 13.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 589,996 shares of the biotechnology company's stock after acquiring an additional 67,929 shares during the quarter.

    Comment?

  12. Intec Pharma (NTEC) Upgraded by ValuEngine to "Buy"Read the original story w/Photo

    Saturday Nov 17 | Daily Political

    A number of other research firms have also recently commented on NTEC. Zacks Investment Research cut Intec Pharma from a buy rating to a hold rating in a research note on Thursday, November 8th.

    Comment?

  13. Intec Pharma (NTEC) PT Set at $15.00 by OppenheimerRead the original story w/Photo

    Saturday Nov 17 | IntersportsWire

    The brokerage presently has a "buy" rating on the biotechnology company's stock. Oppenheimer's price target would suggest a potential upside of 152.95% from the stock's previous close.

    Comment?

  14. Zacks: Brokerages Expect Intec Pharma (NTEC) Will Announce Earnings of -$0.31 Per ShareRead the original story w/Photo

    Nov 11, 2018 | Daily Political

    Brokerages expect Intec Pharma to report earnings per share for the current fiscal quarter, according to Zacks Investment Research . Zero analysts have provided estimates for Intec Pharma's earnings, with estimates ranging from to .

    Comment?

  15. Zacks: Analysts Anticipate Intec Pharma (NTEC) to Post -$0.30 Earnings Per ShareRead the original story w/Photo

    Nov 9, 2018 | IntersportsWire

    Brokerages expect Intec Pharma to post earnings per share of for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Intec Pharma's earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  16. -$0.30 EPS Expected for Intec Pharma (NTEC) This QuarterRead the original story w/Photo

    Nov 4, 2018 | AmericanBankingNews.com

    Analysts expect Intec Pharma to post earnings of per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Intec Pharma's earnings, with estimates ranging from to .

    Comment?

  17. Intec Pharma (NTEC) Receives Consensus Rating of "Buy" from BrokeragesRead the original story w/Photo

    Oct 31, 2018 | IntersportsWire

    Shares of Intec Pharma have been given an average rating of "Buy" by the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company.

    Comment?

  18. Aytu Bioscience (AYTU) versus Intec Pharma (NTEC) Head-To-Head ComparisonRead the original story w/Photo

    Oct 30, 2018 | IntersportsWire

    Aytu Bioscience and Intec Pharma are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk. Aytu Bioscience has higher revenue and earnings than Intec Pharma.

    Comment?

  19. Intec Pharma (NTEC) Given a $16.00 Price Target at HC WainwrightRead the original story w/Photo

    Oct 25, 2018 | IntersportsWire

    The brokerage currently has a buy rating on the biotechnology company's stock. A number of other equities research analysts have also weighed in on the company.

    Comment?

  20. -$0.30 EPS Expected for Intec Pharma (NTEC) This QuarterRead the original story w/Photo

    Oct 11, 2018 | AmericanBankingNews.com

    Wall Street brokerages expect that Intec Pharma will post earnings of per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Intec Pharma's earnings.

    Comment?